Menlo Park-based company CohBar, Inc. is making strides in the development of mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. Currently, the company is focusing on the clinical trial of its therapeutic CB4211, which is in Phase 1a/1b and shows promise for the treatment of nonalcoholic steatohepatitis and obesity. Additionally, CohBar, Inc. is conducting preclinical studies on its CB5138 Analogs, which could potentially treat idiopathic pulmonary fibrosis and other fibrotic diseases. Since its inception in 2007, the clinical stage biotechnology company has been dedicated to innovation in the biotech sector.